SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis

• Main Authors: Jakob Höppner (Author), Vincent Casteleyn (Author), Robert Biesen (Author), Thomas Rose (Author), Wolfram Windisch (Author), Gerd Rüdiger Burmester (Author), Elise Siegert (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Systemic Sclerosis (SSc) is a clinically heterogeneous disease that includes an upregulation of type I interferons (IFNs). The aim of this observational study was to investigate the IFN-regulated protein Sialic Acid-Binding Ig-like Lectin 1 (SIGLEC-1) as a biomarker for disease phenotype, therapeutic response, and differential diagnosis in SSc. Levels of SIGLEC-1 expression on monocytes of 203 SSc patients were determined in a cross-sectional and longitudinal analysis using multicolor flow cytometry, then compared to 119 patients with other rheumatic diseases and 13 healthy controls. SSc patients higher SIGLEC-1 expression on monocytes (2097.94 ± 2134.39) than HCs (1167.45 ± 380.93; <i>p</i> = 0.49), but significantly lower levels than SLE (8761.66 ± 8325.74; <i>p</i> < 0.001) and MCTD (6414.50 ± 1846.55; <i>p</i> < 0.001) patients. A positive SIGELC-1 signature was associated with reduced forced expiratory volume (<i>p</i> = 0.007); however, we were unable to find an association with fibrotic or vascular disease manifestations. SIGLEC-1 remained stable over time and was independent of changes in immunosuppressive therapy. However, SIGLEC-1 is suitable for differentiating SSc from other connective tissue diseases. SIGLEC-1 expression on monocytes can be useful in the differential diagnosis of connective tissue disease but not as a biomarker for SSc disease manifestations or activity.

Item Description

10.3390/ph15101198
1424-8247